menu
    • menu
    [{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Lahey Hospital & Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"ATH-63","moa":"TNF alpha","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Athos Therapeutics \/ Lahey Hospital & Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Athos Therapeutics \/ Lahey Hospital & Medical Center"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Athos Therapeutics","amount2":0.71999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.71999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"Athos Therapeutics \/ Athos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Athos Therapeutics \/ Athos Therapeutics"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ATH-063","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Athos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"ATH-063","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Athos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Athos Therapeutics

    Menu

    Athos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Athos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Athos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATH-063

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $35.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Athos, an Autoimmune and Cancer Biotech, is Raising $35M for Clinical Trials

                            Details : Funds will support ATH-063, a small molecule therapeutic targeting inflammation and mucosal healing in Crohn’s Disease and Ulcerative Colitis.

                            Brand Name : ATH-063

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2024

                            Lead Product(s) : ATH-063

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $35.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Athos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Athos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATH-063

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

                            Details : ATH-063 is a first-in-class, oral, small molecule, genomic regulator acts both by suppressing pro-inflammatory responses and inducing direct mucosal healing, being developed for inflammatory bowel diseases, other autoimmune diseases and solid cancers.

                            Brand Name : ATH-063

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 29, 2023

                            Lead Product(s) : ATH-063

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Athos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Athos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATH-63

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Lahey Hospital & Medical Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Diseas...

                            Details : Athos to perform molecular analysis of biopsies from de-identified Inflammatory Bowel Disease patient having ATH-63, samples from Lahey Hospital & Medical Center based in Burlington, Massachusetts.

                            Brand Name : ATH-63

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 11, 2022

                            Lead Product(s) : ATH-63

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Lahey Hospital & Medical Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Athos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Athos Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Formycon

                            Deal Size : $720.7 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Formycon AG And Athos KG Announce Closing of Transaction to Acquire Biosimilar Assets FYB201 And FYB202 As Wel...

                            Details : The structure of the transaction will involve Formycon acquiring all the rights in FYB202, a biosimilar candidate for Stelara® (ustekinumab), as well as a 50% share in FYB201, a biosimilar candidate for Lucentis®2 (ranibizumab).

                            Brand Name : FYB202

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 10, 2022

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Formycon

                            Deal Size : $720.7 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth